WuXi PharmaTech's Leader Explains How U.S. Economic Tremors Tore Through American Subsidiary, Buried Five Years of Company Earnings
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of WuXi PharmaTech, China's top contract research organization, has spelled out for the first time in detail how its ill-timed acquisition of an American biologics manufacturing and testing outfit, lashed by the tempests of the West's financial crisis, triggered a massive loss that wiped out five years of earnings